XERS
Xeris Biopharma Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.43
−1.86%Aug 9, 2026, 11:54 UTC
Xeris Biopharma received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering the use of Keveyis, expected to extend intellectual property protection until 2039.
Source:Aug 6, 2026, 11:00 UTC
Xeris Biopharma Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting net product revenue growth of 34% year-over-year.
Jul 17, 2026, 00:00 UTC
Xeris Biopharma Holdings, Inc. issued shares of its common stock upon conversion of $10.5 million aggregate principal amount of its 8.00% Convertible Senior Notes due 2028.
Jun 30, 2026, 00:00 UTC
Matthew Pauls was appointed as a Class I director of Palvella Therapeutics, Inc.
Jun 11, 2026, 00:00 UTC
Xeris Biopharma Holdings, Inc. exchanged approximately $23 million aggregate principal of its 8.00% Convertible Senior Notes due 2028 for cash and newly issued common stock in a private debt-for-equity exchange.
Source: